Cadrenal Therapeutics, Inc. (CVKD)
NASDAQ:CVKD
Want to see CVKD full AI Analyst Report?
CVKD Stock Chart & Stats
$5.22
-$1.27(-7.12%)
At close: 4:00 PM EST
$5.22
-$1.27(-7.12%)
Day’s Range― - ―
52-Week Range$4.15 - $15.99
Previous CloseN/A
Volume16.20K
Average Volume (3M)57.36K
Market Cap
$12.74M
Enterprise Value$11.92M
Total Cash (Recent Filing)$2.31M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.15
Next Earnings
Aug 06, 2026EPS Estimate
-1.55Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.63
Shares Outstanding2,868,247
10 Day Avg. Volume57,981
30 Day Avg. Volume57,363
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)4.94
Price to Sales (P/S)0.00
P/FCF Ratio-1.07
Enterprise Value/Market Cap0.94
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-12.47K
Enterprise Value/Ebitda-0.99
Forecast
1Y Price Target
$29.00Price Target Upside455.56% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-5.61
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
FDA-guided Phase 3 PathRegulatory clarity from an End-of-Phase 2 meeting materially reduces program execution risk: a defined randomized, blinded Phase 3 design and endpoints create a clear development roadmap and timeline, improving the probability that clinical and regulatory milestones drive durable value creation over the next 2–4 years.
First-in-class Mechanism With Expansion PotentialA first-in-class 12-LOX mechanism provides a competitive moat if efficacy and safety are confirmed; preclinical signals in metabolic disease suggest a multi-indication pathway that can diversify long-term commercial opportunity beyond the core HIT indication, supporting strategic optionality and upside.
Very Low Financial LeverageZero reported debt preserves financial flexibility and limits fixed obligations, which is especially valuable for a clinical-stage biopharma that will rely on equity and partnerships. Low leverage reduces downside risk and gives management room to fund trials or negotiate collaborations without interest-pressure constraints.
Bears Say
Pre-revenue With Widening LossesSustained pre-revenue status and growing net losses signal that operating expenses are outpacing any near-term commercial inflows; over multiple quarters this erodes shareholder capital and increases dependence on external funding, making long-term program continuity contingent on successful financing or partnerships.
Material Negative Cash Flow / Accelerating BurnConsistent negative operating and free cash flow indicate the company is consuming capital to advance clinical programs. Accelerating burn reduces runway absent financing and forces management to prioritize spending, which can delay programs or force dilutive financings, creating persistent execution risk for development timelines.
Financing-driven Dilution RiskReliance on warrant-based financings injects near-term cash but creates contingent dilution and complex future claim structures. Repeated use of such financing can degrade equity value over time, constrain upside for existing shareholders, and complicate capital planning across multi-year development programs.
Cadrenal Therapeutics, Inc. News
CVKD FAQ
What was Cadrenal Therapeutics, Inc.’s price range in the past 12 months?
Cadrenal Therapeutics, Inc. lowest stock price was $4.14 and its highest was $15.99 in the past 12 months.
What is Cadrenal Therapeutics, Inc.’s market cap?
Cadrenal Therapeutics, Inc.’s market cap is $12.74M.
When is Cadrenal Therapeutics, Inc.’s upcoming earnings report date?
Cadrenal Therapeutics, Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 60 days.
How were Cadrenal Therapeutics, Inc.’s earnings last quarter?
Cadrenal Therapeutics, Inc. released its earnings results on May 07, 2026. The company reported -$1.04 earnings per share for the quarter, missing the consensus estimate of N/A by -$1.04.
Is Cadrenal Therapeutics, Inc. overvalued?
According to Wall Street analysts Cadrenal Therapeutics, Inc.’s price is currently Undervalued.
Does Cadrenal Therapeutics, Inc. pay dividends?
Cadrenal Therapeutics, Inc. does not currently pay dividends.
What is Cadrenal Therapeutics, Inc.’s EPS estimate?
Cadrenal Therapeutics, Inc.’s EPS estimate is -1.55.
How many shares outstanding does Cadrenal Therapeutics, Inc. have?
Cadrenal Therapeutics, Inc. has 2,868,247 shares outstanding.
What happened to Cadrenal Therapeutics, Inc.’s price movement after its last earnings report?
Cadrenal Therapeutics, Inc. reported an EPS of -$1.04 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.431%.
Which hedge fund is a major shareholder of Cadrenal Therapeutics, Inc.?
Currently, no hedge funds are holding shares in CVKD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Cadrenal Therapeutics, Inc.
Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel therapy with orphan drug indication for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.
CVKD Stock 12 Month Forecast
Average Price Target
$29.00
▲(455.56% Upside)
Technical Analysis
Daré Bioscience
―
Vyome Holdings
―
Collplant Holdings
―
Lunai Bioworks
―
Tao Synergies
―
Ownership Overview
13.01% Insiders
2.05% Mutual Funds
0.06% Other Institutional Investors
83.08% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---